Compare NMAI & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMAI | FLGT |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 511.0M |
| IPO Year | N/A | 2016 |
| Metric | NMAI | FLGT |
|---|---|---|
| Price | $14.50 | $19.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 87.3K | ★ 223.8K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | N/A | $12.18 |
| P/E Ratio | $22.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.99 | $13.46 |
| 52 Week High | $15.06 | $31.04 |
| Indicator | NMAI | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 55.01 |
| Support Level | $13.48 | $19.20 |
| Resistance Level | $15.06 | $20.24 |
| Average True Range (ATR) | 0.19 | 0.53 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 54.56 | 69.87 |
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.